IMS Health expands suite of syndicated analytics with PharmaDeals acquisition
IMS Health, a provider of information, services and technology for the healthcare industry, has acquired PharmaDeals, a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the global pharmaceutical industry.
PharmaDeals, the U.K.-based subsidiary of PharmaVentures, maintains a web-based subscription database containing more than 46,000 records of industry transactions and 16 years of historical data. PharmaDeals will become part of IMS’s syndicated analytics and insights that help healthcare clients with their real-time decision making in the areas of market assessment, forecasting, and lifecycle and portfolio management. This addition complements IMS’s portfolio of competitive intelligence capabilities, which include company benchmarking, sales force sizing and therapeutic analyses. Clients use this intelligence to analyze the market, the competition and new growth opportunities.
“We are very excited to extend our business analytics and insights to deliver even greater value to clients,” said Anne Delaney, general manager, IMS. “To properly assess the value of partnerships and licensing opportunities, clients need to understand the landscape of transactions in the context of real-world evidence. Now we can bring these perspectives together in a unique and innovative way as the industry continues to transform and healthcare stakeholders look for new partnerships and opportunities for growth.”
Dr. Fintan Walton, chief executive of PharmaVentures, said, “The PharmaDeals database is the recognized gold standard in terms of its coverage, quality and depth. I am confident that integrating these insights with IMS’s robust information and technology assets will open up a new set of possibilities for decision making.”